Company Filing History:
Years Active: 2025
Title: Dhanunjay Kumar Dogiparti: Innovator in Pharmaceutical Compositions
Introduction
Dhanunjay Kumar Dogiparti is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug formulations. His work focuses on improving the efficacy and delivery of medications, which is crucial in the treatment of various diseases.
Latest Patents
Dhanunjay Kumar Dogiparti holds a patent for "Amorphous pharmaceutical compositions of abiraterone acetate." This invention relates to a pharmaceutical composition that comprises a solid dispersion of amorphous abiraterone acetate along with one or more pharmaceutically acceptable excipients. The composition is designed to have improved solubility, stability, and bioavailability, with no positive food effect. Additionally, the patent includes a method for preparing this composition, a dosage form that incorporates it, and its application as a medicament for treating prostate cancer.
Career Highlights
Dhanunjay is associated with Suven Life Sciences Limited, a company known for its focus on drug discovery and development. His role in the company has allowed him to contribute to significant advancements in pharmaceutical sciences. His expertise in formulating effective drug compositions has positioned him as a valuable asset in the industry.
Collaborations
Dhanunjay has worked alongside talented colleagues such as Ramakrishna Nirogi and Koteshwara Mudigonda. Their collaborative efforts have fostered an environment of innovation and creativity, leading to the development of groundbreaking pharmaceutical solutions.
Conclusion
Dhanunjay Kumar Dogiparti's contributions to pharmaceutical compositions exemplify the importance of innovation in medicine. His patent for amorphous abiraterone acetate showcases his commitment to improving treatment options for patients with prostate cancer. Through his work, he continues to make a significant impact in the field of pharmaceuticals.